Human blood plasma as source for biotherapeutics is very limited and safety concerns still persist, leading to a growing need for recombinant plasma proteins. In addition, glycosylation patterns of most plasma proteins are very complex and represent a huge challenge to recombinant protein expression. With a comprehensive portfolio of glyco-optimized human cell lines, the CAP-Go expression system paves the way for recombinant plasma proteins.
Recombinant human C1 Inhibitor (C1-INH)
C1-Inhibitor deficiency patients suffer from an inherited form of angioedema that are currently predominantly being treated with intravenous injections of C1 Inhibitor purified from human serum. CEVEC´s CAP-Go derived C1 Inhibitor showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. This result, in combination with excellent specific activities of CAP-Go derived C1 Inh and commercially attractive production yields, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.
CEVEC and global biotechnology leader CSL Limited signed an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP®Go technology in May 2018.
See also: Press release on CEVEC & CSL agreement
For further information contact firstname.lastname@example.org or give us a call at +49 221 46020800.